

Design, synthesis and in vitro evaluations of new cyclotriphosphazenes as safe drug candidates

Elif Yıldız Gül^{a,**}, Büşra Tiryaki^{b,**}, Buse Köse^a, Nuri Öztürk^b, Elif Okutan^c, Burcu Dedeoğlu^c, Esra Tanrıverdi Eçik^{a,*}

^a Department of Chemistry, Faculty of Science, Atatürk University, Erzurum, Türkiye

^b Department of Molecular Biology and Genetics, Gebze Technical University, Kocaeli, Türkiye

^c Department of Chemistry, Gebze Technical University, Kocaeli, Türkiye

*Department of Chemistry, Faculty of Science, Atatürk University, Erzurum, Türkiye

E-mail: esra.ecik@atauni.edu.tr ([E. Tanrıverdi-Eçik](#))

**E. Yıldız-Gül and B. Tiryaki equally contributed to this manuscript.




Fig S1. The MALDI TOF mass spectrum of compound **1**




Fig S2. The proton decoupled ^{31}P NMR spectrum of compound **1**




Fig S3. The ^1H NMR spectrum of compound **1**




Fig S4. The ^{13}C NMR spectrum of compound **1**




Fig S5. The MALDI TOF mass spectrum of compound **2**




Fig S6. The proton decoupled ^{31}P NMR spectrum of compound **2**




Fig S7. The ¹H NMR spectrum of compound 2




Fig S8. The ¹³C NMR spectrum of compound 2




Fig S9. The MALDI TOF mass spectrum of compound **3**




Fig S10. The proton decoupled ³¹P NMR spectrum of compound **3**




Fig S11. The ¹H NMR spectrum of compound 3




Fig S12. The ¹³C NMR spectrum of compound 3




Fig S13. The MALDI TOF mass spectrum of compound **4**




Fig S14. The proton decoupled ^{31}P NMR spectrum of compound **4**




Fig S15. The ¹H NMR spectrum of compound 4




Fig S16. The ¹³C NMR spectrum of compound 4




Fig S17. The MALDI TOF mass spectrum of compound **5**




Fig S18. The proton decoupled ^{31}P NMR spectrum of compound **5**




Fig S19. The ¹H NMR spectrum of compound 5




Fig S20. The ¹³C NMR spectrum of compound 5




Fig S21. The MALDI TOF mass spectrum of compound **6**




Fig S22. The proton decoupled ^{31}P NMR spectrum of compound **6**




Fig S23. The ¹H NMR spectrum of compound 6




Fig S24. The ¹³C NMR spectrum of compound 6




Fig S25. The proton decoupled ^{31}P NMR spectrum of compound 7




Fig S26. The ^1H NMR spectrum of compound 7




Fig S27. The ¹³C NMR spectrum of compound **7**




Fig S28. The MALDI TOF mass spectrum of compound **8**




Fig S29. The proton decoupled ^{31}P NMR spectrum of compound **8**




Fig S30. The ^1H NMR spectrum of compound **8**




Fig S31. The ^{13}C NMR spectrum of compound **8**




Fig S32. The MALDI TOF mass spectrum of compound **9**




Fig S33. The proton decoupled ^{31}P NMR spectrum of compound **9**




Fig S34. The ^1H NMR spectrum of compound **9**




Fig S35. The ^{13}C NMR spectrum of compound **9**




Fig S36. The MALDI TOF mass spectrum of compound **10**




Fig S37. The proton decoupled ^{31}P NMR spectrum of compound **10**




Fig S38. The ^1H NMR spectrum of compound **10**




Fig S39. The ^{13}C NMR spectrum of compound **10**




Fig S40. Real-time bioluminescence graph representing circadian oscillations in untreated (UT) and 0.5% DMSO treated U2OS cells. Graphs represented raw data were illustrated with GraphPad. Period and amplitude data were analyzed using Student's-t test, revealing no significant differences between groups. Period and amplitude values are represented mean \pm SD ($n = 3$). Statistical significance was set at $*p < 0.01$.

Table S1. XLOGP values computed by SwissADME web server.

Compound	1	2	3	4	5	6	7	8	9	10
XLOGP	1.75	-1.03	-0.59	5.39	1.36	0.84	4.77	-2.56	-1.39	-5.21

Table S2. Colony Formation values.

Compound No	Replicates	Colony Numbers		Average		Plating Efficiency		Plating Efficiency (%)		Plating Efficiency (%) Normalized to DMSO		Plating Efficiency Normalized to DMSO	
		Min Dose	Max Dose	Min Dose	Max Dose	Min Dose	Max Dose	Min Dose	Max Dose	Min Dose	Max Dose	Min Dose	Max Dose
1	R1	165,00	152,00	179,33	162,33	0,36	0,32	35,87	32,47	61,91	56,04	0,62	0,56
	R2	191,00	169,00										
	R3	182,00	166,00										
2	R1	153,00	76,00	167,67	84,67	0,34	0,17	33,53	16,93	57,88	29,23	0,58	0,29
	R2	195,00	92,00										
	R3	155,00	86,00										
3	R1	189,00	150,00	182,67	152,00	0,37	0,30	36,53	30,40	63,06	52,47	0,63	0,52
	R2	194,00	158,00										
	R3	165,00	148,00										
4	R1	153,00	57,00	169,67	62,67	0,34	0,13	33,93	12,53	58,57	21,63	0,59	0,22
	R2	180,00	68,00										
	R3	176,00	63,00										
5	R1	176,00	107,00	163,67	114,33	0,33	0,23	32,73	22,87	56,50	39,47	0,57	0,39
	R2	170,00	122,00										
	R3	145,00	114,00										
6	R1	219,00	187,00	209,00	190,33	0,42	0,38	41,80	38,07	72,15	65,71	0,72	0,66
	R2	216,00	195,00										
	R3	192,00	189,00										
7	R1	190,00	127,00	196,67	129,33	0,39	0,26	39,33	25,87	67,89	44,65	0,68	0,45
	R2	208,00	141,00										
	R3	192,00	120,00										
8	R1	193,00	132,00	180,33	134,33	0,36	0,27	36,07	26,87	62,26	46,38	0,62	0,46
	R2	175,00	135,00										
	R3	173,00	136,00										
9	R1	215,00	161,00	207,67	173,33	0,42	0,35	41,53	34,67	71,69	59,84	0,72	0,60
	R2	228,00	185,00										
	R3	180,00	174,00										
10	R1	153,00	77,00	166,33	67,33	0,33	0,13	33,27	13,47	57,42	23,25	0,57	0,23
	R2	185,00	75,00										
	R3	161,00	50,00										
DMSO Control	R1	280,00	280,00	289,67	289,67	0,58	0,58	57,93	57,93	100,00	100,00	1,00	1,00
	R2	291,00	291,00										
	R3	298,00	298,00										